Neuropeptides in epilepsy

Neuropeptides

Volumn 47, Issue 6, 2013, Pages 467-475

  Kovac, Stjepana ^a   Walker, Matthew C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AAV; Dynorphin; Epilepsy; Galanin; Ghrelin; Neuropeptide Y; Seizures; Somatostatin; Substance P; Tachykinin; Viral vector

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; DYNORPHIN; GALANIN; GHRELIN; NEUROPEPTIDE; NEUROPEPTIDE Y; SOMATOSTATIN; SPANTIDE II; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TACHYKININ; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMYGDALOID NUCLEUS; ANTICONVULSANT ACTIVITY; BRAIN STEM; ENZYME ACTIVITY; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; GENERALIZED EPILEPSY; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; LOCUS CERULEUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEIZURE; SEIZURE SUSCEPTIBILITY; STRIA TERMINALIS; TEMPORAL LOBE EPILEPSY; THALAMUS; TRANSLATIONAL RESEARCH;

AAV; DYNORPHIN; EPILEPSY; GALANIN; GHRELIN; NEUROPEPTIDE Y; SEIZURES; SOMATOSTATIN; SUBSTANCE P; TACHYKININ; VIRAL VECTOR;

ANIMALS; DYNORPHINS; EPILEPSY; GALANIN; GHRELIN; HUMANS; MICE; NEUROPEPTIDE Y; NEUROPEPTIDES; RATS; SOMATOSTATIN; SUBSTANCE P;

EID: 84887995916     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2013.10.015     Document Type: Review

References (138)

1. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., Polak J.M. Neuropeptide Y distribution in the rat brain. Science 1983, 221:877-879.
2. Aourz N., De Bundel D., Stragier B., Clinckers R., Portelli J., Michotte Y., Smolders I. Rat hippocampal somatostatin sst3 and sst4 receptors mediate anticonvulsive effects in vivo: indications of functional interactions with sst2 receptors. Neuropharmacology 2011, 61:1327-1333.
3. Aslan A., Yildirim M., Ayyildiz M., Güven A., Agar E. The role of nitric oxide in the inhibitory effect of ghrelin against penicillin-induced epileptiform activity in rat. Neuropeptides 2009, 43:295-302.
4. Baraban S.C. Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 2004, 38:261-265.
5. Baraban S.C., Tallent M.K. Interneuron Diversity series: Interneuronal neuropeptides-endogenous regulators of neuronal excitability. Trends Neurosci. 2004, 27:135-142.
6. Barreto S.G., Bazargan M., Zotti M., Hussey D.J., Sukocheva O.A., Peiris H., Leong M., Keating D.J., Schloithe A.C., Carati C.J., Smith C., Toouli J., Saccone G.T.P. Galanin receptor 3 - a potential target for acute pancreatitis therapy. Neurogastroenterol. Motil. 2011, 23:e141-151.
7. Bartfai T., Lu X., Badie-Mahdavi H., Barr A.M., Mazarati A., Hua X.-Y., Yaksh T., Haberhauer G., Ceide S.C., Trembleau L., Somogyi L., Kröck L., Rebek J. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc. Natl. Acad. Sci. USA 2004, 101:10470-10475.
8. Benarroch E.E. Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology 2009, 72:1016-1020.
9. Bijak M. Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes. Neurosci. Lett. 1999, 268:115-118.
10. Boehm S., Betz H. Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors. J. Neurosci. 1997, 17:4066-4075.
11. Branchek T., Smith K.E., Walker M.W. Molecular biology and pharmacology of galanin receptors. Ann. N. Y. Acad. Sci. 1998, 863:94-107.
12. Burazin T.C., Larm J.A., Ryan M.C., Gundlach A.L. Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. Eur. J. Neurosci. 2000, 12:2901-2917.
13. Camiña J.P. Cell biology of the ghrelin receptor. J. Neuroendocrinol. 2006, 18:65-76.
14. Casillas-Espinosa P.M., Powell K.L., O'Brien T.J. Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy. Epilepsia 2012, 53(Suppl 9):41-58.
15. Chavkin C., James I.F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982, 215:413-415.
16. Chee M.J.S., Colmers W.F. Y eat?. Nutrition 2008, 24:869-877.
17. Cheung A., Newland P.L., Zaben M., Attard G.S., Gray W.P. Intracellular nitric oxide mediates neuroproliferative effect of neuropeptide y on postnatal hippocampal precursor cells. J. Biol. Chem. 2012, 287:20187-20196.
18. Colmers W.F., Lukowiak K., Pittman Q.J. Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J. Physiol. (London) 1987, 383:285-299.
19. Colmers W.F., Klapstein G.J., Fournier A., St-Pierre S., Treherne K.A. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br. J. Pharmacol. 1991, 102:41-44.
20. Consolo S., Baldi G., Russi G., Civenni G., Bartfai T., Vezzani A. Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. Proc. Natl. Acad. Sci. USA 1994, 91:8047-8051.
21. Cowley M.A., Smith R.G., Diano S., Tschöp M., Pronchuk N., Grove K.L., Strasburger C.J., Bidlingmaier M., Esterman M., Heiman M.L., Garcia-Segura L.M., Nillni E.A., Mendez P., Low M.J., Sotonyi P., Friedman J.M., Liu H., Pinto S., Colmers W.F., Cone R.D., Horvath T.L. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37:649-661.
22. De Lanerolle N.C., Kim J.H., Robbins R.J., Spencer D.D. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res. 1989, 495:387-395.
23. De Quidt M.E., Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis. Neuroscience 1986, 18:545-618.
24. De Tisi J., Bell G.S., Peacock J.L., McEvoy A.W., Harkness W.F.J., Sander J.W., Duncan J.S. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet 2011, 378:1388-1395.
25. Decressac M., Barker R.A. Neuropeptide Y and its role in CNS disease and repair. Exp. Neurol. 2012, 238:265-272.
26. Decressac M., Prestoz L., Veran J., Cantereau A., Jaber M., Gaillard A. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol. Dis. 2009, 34:441-449.
27. Decressac M., Wright B., Tyers P., Gaillard A., Barker R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol. 2010, 226:24-32.
28. Decressac M., Wright B., David B., Tyers P., Jaber M., Barker R.A., Gaillard A. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus 2011, 21:233-238.
29. Dumont Y., Fournier A., Quirion R. Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain. J. Neurosci. 1998, 18:5565-5574.
30. Dumont Y., Jacques D., Bouchard P., Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 1998, 402:372-384.
31. Duncan J.S., Sander J.W., Sisodiya S.M., Walker M.C. Adult epilepsy. Lancet 2006, 367:1087-1100.
32. El Bahh B., Balosso S., Hamilton T., Herzog H., Beck-Sickinger A.G., Sperk G., Gehlert D.R., Vezzani A., Colmers W.F. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur. J. Neurosci. 2005, 22:1417-1430.
33. Fisone G., Wu C.F., Consolo S., Nordström O., Brynne N., Bartfai T., Melander T., Hökfelt T. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc. Natl. Acad. Sci. USA 1987, 84:7339-7343.
34. Foti S., Haberman R.P., Samulski R.J., McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther. 2007, 14:1534-1536.
35. Gobbi M., Gariboldi M., Piwko C., Hoyer D., Sperk G., Vezzani A. Distinct changes in peptide YY binding to, and mRNA levels of, Y1 and Y2 receptors in the rat hippocampus associated with kindling epileptogenesis. J. Neurochem. 1998, 70:1615-1622.
36. Goldstein A., Tachibana S., Lowney L.I., Hunkapiller M., Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. USA 1979, 76:6666-6670.
37. Gøtzsche C.R., Nikitidou L., Sørensen A.T., Olesen M.V., Sørensen G., Christiansen S.H., Ängehagen M., Woldbye D.P., Kokaia M. Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. Neurobiol Dis. 2012, 45:288-296.
38. Granata R., Settanni F., Biancone L., Trovato L., Nano R., Bertuzzi F., Destefanis S., Annunziata M., Martinetti M., Catapano F., Ghè C., Isgaard J., Papotti M., Ghigo E., Muccioli G. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling. Endocrinology 2007, 148:512-529.
39. Greber S., Schwarzer C., Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 1994, 113:737-740.
40. Haberman R.P., Samulski R.J., McCown T.J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 2003, 9:1076-1080.
41. Habert-Ortoli E., Amiranoff B., Loquet I., Laburthe M., Mayaux J.F. Molecular cloning of a functional human galanin receptor. Proc. Natl. Acad. Sci. USA 1994, 91:9780-9783.
42. Hammers A., Asselin M.-C., Hinz R., Kitchen I., Brooks D.J., Duncan J.S., Koepp M.J. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 2007, 130:1009-1016.
43. Hohmann J.G., Juréus A., Teklemichael D.N., Matsumoto A.M., Clifton D.K., Steiner R.A. Distribution and regulation of galanin receptor 1 messenger RNA in the forebrain of wild type and galanin-transgenic mice. Neuroscience 2003, 117:105-117.
44. Hökfelt T., Xu Z.Q., Shi T.J., Holmberg K., Zhang X. Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Ann. N. Y. Acad. Sci. 1998, 863:252-263.
45. Howell O.W., Doyle K., Goodman J.H., Scharfman H.E., Herzog H., Pringle A., Beck-Sickinger A.G., Gray W.P. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J. Neurochem. 2005, 93:560-570.
46. Howell O.W., Silva S., Scharfman H.E., Sosunov A.A., Zaben M., Shatya A., McKhann G., Herzog H., Laskowski A., Gray W.P. Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol. Dis. 2007, 26:174-188.
47. Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Feniuk W., Humphrey P.P., O'Carroll A.M., Patel Y.C., Schonbrunn A., Taylor J.E. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 1995, 16:86-88.
48. Hurd Y.L., Herkenham M. The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis. Neuroscience 1995, 64:571-586.
49. Jacoby A.S., Hort Y.J., Constantinescu G., Shine J., Iismaa T.P. Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Brain Res. Mol. Brain Res. 2002, 107:195-200.
50. Kageyama H., Takenoya F., Hirako S., Wada N., Kintaka Y., Inoue S., Ota E., Ogawa T., Shioda S. Neuronal circuits involving neuropeptide Y in hypothalamic arcuate nucleus-mediated feeding regulation. Neuropeptides 2012, 46:285-289.
51. Kalinichev M., Bradford A., Bison S., Lucas A., Sartori I., Garbati N., Andreetta F., Bate S., Austin N.E., Jones D.N.C., Read K.D., Alvaro G., Large C.H. Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat. Epilepsia 2010, 51:1543-1551.
52. Kanemitsu Y., Hosoi M., Zhu P.J., Weight F.F., Peoples R.W., McLaughlin J.S., Zhang L. Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism. Mol. Cell. Neurosci. 2003, 24:525-537.
53. Kanter-Schlifke I., Toft Sørensen A., Ledri M., Kuteeva E., Hökfelt T., Kokaia M. Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity. Neuroscience 2007, 150:984-992.
54. Klapstein G.J., Colmers W.F. 4-Aminopyridine and low Ca2+ differentiate presynaptic inhibition mediated by neuropeptide Y, baclofen and 2-chloroadenosine in rat hippocampal CA1 in vitro. Br. J. Pharmacol. 1992, 105:470-474.
55. Klemp K., Woldbye D.P. Repeated inhibitory effects of NPY on hippocampal CA3 seizures and wet dog shakes. Peptides 2001, 22:523-527.
56. Kofler N., Kirchmair E., Schwarzer C., Sperk G. Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats. Neurosci. Lett. 1997, 230:129-132.
57. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
58. Kovac S., Megalogeni M., Walker M. In vitro effects of neuropeptide Y in rat neocortical and hippocampal tissue. Neurosci. Lett. 2011, 492:43-46.
59. Kozhemyakin M., Rajasekaran K., Todorovic M.S., Kowalski S.L., Balint C., Kapur J. Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus. Neurobiol. Dis. 2013, 54:94-104.
60. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645.
61. Kuzmin A., Madjid N., Terenius L., Ogren S.O., Bakalkin G. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology 2006, 31:1928-1937.
62. Lang R., Gundlach A.L., Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 2007, 115:177-207.
63. Larhammar D. Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 1996, 62:1-11.
64. Laskowski A., Howell O.W., Sosunov A.A., Sosuov A.A., McKhann G., Gray W.P. NPY mediates basal and seizure-induced proliferation in the subcallosal zone. Neuroreport 2007, 18:1005-1008.
65. Lazarowski A., Czornyj L., Lubienieki F., Girardi E., Vazquez S., D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007, 48(Suppl 5):140-149.
66. Lerner J.T., Sankar R., Mazarati A.M. Galanin and epilepsy. Cell. Mol. Life Sci. 2008, 65:1864-1871.
67. Liu H., Mazarati A.M., Katsumori H., Sankar R., Wasterlain C.G. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc. Natl. Acad. Sci. USA 1999, 96:5286-5291.
68. Lin E.J., Richichi C., Young D., Baer K., Vezzani A., During M.J. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci. 2003, 18:2087-2092.
69. Loacker S., Sayyah M., Wittmann W., Herzog H., Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 2007, 130:1017-1028.
70. Lu X., Roberts E., Xia F., Sanchez-Alavez M., Liu T., Baldwin R., Wu S., Chang J., Wasterlain C.G., Bartfai T. GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc. Natl. Acad. Sci. USA 2010, 107:15229-15234.
71. Mazarati A.M. Galanin and galanin receptors in epilepsy. Neuropeptides 2004, 38:331-343.
72. Mazarati A.M., Telegdy G. Effects of somatostatin and anti-somatostatin serum on picrotoxin-kindled seizures. Neuropharmacology 1992, 31:793-797.
73. Mazarati A.M., Wasterlain C.G. Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neurosci. Lett. 2002, 331:123-127.
74. Mazarati A.M., Liu H., Soomets U., Sankar R., Shin D., Katsumori H., Langel U., Wasterlain C.G. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J. Neurosci. 1998, 18:10070-10077.
75. Mazarati A.M., Hohmann J.G., Bacon A., Liu H., Sankar R., Steiner R.A., Wynick D., Wasterlain C.G. Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 2000, 20:6276-6281.
76. Mazarati A., Lu X., Shinmei S., Badie-Mahdavi H., Bartfai T. Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 2004, 128:431-441.
77. McClelland S., Flynn C., Dubé C., Richichi C., Zha Q., Ghestem A., Esclapez M., Bernard C., Baram T.Z. Neuron-restrictive silencer factor-mediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. Ann. Neurol. 2011, 70:454-464.
78. McColl C.D., Jacoby A.S., Shine J., Iismaa T.P., Bekkers J.M. Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal EEGs and altered inhibition in the hippocampus. Neuropharmacology 2006, 50:209-218.
79. McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther. 2006, 14:63-68.
80. McQuiston A.R., Colmers W.F. Neuropeptide Y2 receptors inhibit the frequency of spontaneous but not miniature EPSCs in CA3 pyramidal cells of rat hippocampus. J. Neurophysiol. 1996, 76:3159-3168.
81. Mennicken F., Hoffert C., Pelletier M., Ahmad S., O'Donnell D. Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system. J. Chem. Neuroanat. 2002, 24:257-268.
82. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50:143-150.
83. Mitsukawa K., Lu X., Bartfai T. Galanin, galanin receptors and drug targets. Cell. Mol. Life Sci. 2008, 65:1796-1805.
84. Mogenson G.J., Jones D.L., Yim C.Y. From motivation to action: Functional interface between the limbic system and the motor system. Prog. Neurobiol. 1980, 14:69-97.
85. Moneta D., Richichi C., Aliprandi M., Dournaud P., Dutar P., Billard J.M., Carlo A.S., Viollet C., Hannon J.P., Fehlmann D., Nunn C., Hoyer D., Epelbaum J., Vezzani A. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur. J. Neurosci. 2002, 16:843-849.
86. Morris M.J., Gannan E., Stroud L.M., Beck-Sickinger A.G., O'Brien T.J. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors. Eur. J. Neurosci. 2007, 25:1136-1143.
87. Nikoshkov A., Hurd Y.L., Yakovleva T., Bazov I., Marinova Z., Cebers G., Pasikova N., Gharibyan A., Terenius L., Bakalkin G. Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain. FASEB J. 2005, 19:1543-1545.
88. Noè F., Pool A.-H., Nissinen J., Gobbi M., Bland R., Rizzi M., Balducci C., Ferraguti F., Sperk G., During M.J., Pitkänen A., Vezzani A. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008, 131:1506-1515.
89. O'Donnell D., Ahmad S., Wahlestedt C., Walker P. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J. Comp. Neurol. 1999, 409:469-481.
90. Obay B.D., Tasdemir E., Tümer C., Bilgin H.M., Sermet A. Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats. Peptides 2007, 28:1214-1219.
91. Obay B.D., Taşdemir E., Tümer C., Bilgin H.M., Atmaca M. Dose dependent effects of ghrelin on pentylenetetrazole-induced oxidative stress in a rat seizure model. Peptides 2008, 29:448-455.
92. Oz M., Woods A.S., Shippenberg T., Kaminski R.M. Effects of extracellular pH on the dynorphin A inhibition of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Synapse 2004, 52:84-88.
93. Portelli J., Michotte Y., Smolders I. Ghrelin: an emerging new anticonvulsant neuropeptide. Epilepsia 2012, 53:585-595.
94. Qiu C., Zeyda T., Johnson B., Hochgeschwender U., de Lecea L., Tallent M.K. Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. J. Neurosci. 2008, 28:3567-3576.
95. Reibel S., Nadi S., Benmaamar R., Larmet Y., Carnahan J., Marescaux C., Depaulis A. Neuropeptide Y and epilepsy: varying effects according to seizure type and receptor activation. Peptides 2001, 22:529-539.
96. Richichi C., Lin E.-J.D., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 2004, 24:3051-3059.
97. Rodrigo C., Zaben M., Lawrence T., Laskowski A., Howell O.W., Gray W.P. NPY augments the proliferative effect of FGF2 and increases the expression of FGFR1 on nestin positive postnatal hippocampal precursor cells, via the Y1 receptor. J. Neurochem. 2010, 113:615-627.
98. Saar K., Mazarati A.M., Mahlapuu R., Hallnemo G., Soomets U., Kilk K., Hellberg S., Pooga M., Tolf B.-R., Shi T.S., Hökfelt T., Wasterlain C., Bartfai T., Langel U. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. USA 2002, 99:7136-7141.
99. Schauwecker P.E. Galanin receptor 1 deletion exacerbates hippocampal neuronal loss after systemic kainate administration in mice. PLoS One 2010, 5:e15657.
100. Schmidhuber S.M., Rauch I., Kofler B., Brain S.D. Evidence that the modulatory effect of galanin on inflammatory edema formation is mediated by the galanin receptor 3 in the murine microvasculature. J. Mol. Neurosci. 2009, 37:177-181.
101. Schwarzer C. 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol. Ther. 2009, 123:353-370.
102. Schwarzer C., Williamson J.M., Lothman E.W., Vezzani A., Sperk G. Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience 1995, 69:831-845.
103. Schwarzer C., Kofler N., Sperk G. Up-regulation of neuropeptide Y-Y2 receptors in an animal model of temporal lobe epilepsy. Mol. Pharmacol. 1998, 53:6-13.
104. Simonato M., Romualdi P. Dynorphin and epilepsy. Prog. Neurobiol. 1996, 50:557-583.
105. Sloviter R.S. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987, 235:73-76.
106. Smith K.E., Walker M.W., Artymyshyn R., Bard J., Borowsky B., Tamm J.A., Yao W.J., Vaysse P.J., Branchek T.A., Gerald C., Jones K.A. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J. Biol. Chem. 1998, 273:23321-23326.
107. Sørensen A.T., Kanter-Schlifke I., Carli M., Balducci C., Noe F., During M.J., Vezzani A., Kokaia M. NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus 2008, 18:564-574.
108. Sørensen A.T., Nikitidou L., Ledri M., Lin E.-J.D., During M.J., Kanter-Schlifke I., Kokaia M. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol. 2009, 215:328-333.
109. Spencer E.M., Chandler K.E., Haddley K., Howard M.R., Hughes D., Belyaev N.D., Coulson J.M., Stewart J.P., Buckley N.J., Kipar A., Walker M.C., Quinn J.P. Regulation and role of REST and REST4 variants in modulation of gene expression in in vivo and in vitro in epilepsy models. Neurobiol. Dis. 2006, 24:41-52.
110. Sperk G., Marksteiner J., Gruber B., Bellmann R., Mahata M., Ortler M. Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience 1992, 50:831-846.
111. Stanfield P.R., Nakajima Y., Yamaguchi K. Substance P raises neuronal membrane excitability by reducing inward rectification. Nature 1985, 315:498-501.
112. Stanić D., Mulder J., Watanabe M., Hökfelt T. Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules. J. Comp. Neurol. 2011, 519:1219-1257.
113. Stephen L.J., Kwan P., Brodie M.J. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?. Epilepsia 2001, 42:357-362.
114. Stroud L.M., O'Brien T.J., Jupp B., Wallengren C., Morris M.J. Neuropeptide Y suppresses absence seizures in a genetic rat model. Brain Res. 2005, 1033:151-156.
115. Szybala C., Pritchard E.M., Lusardi T.A., Li T., Wilz A., Kaplan D.L., Boison D. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp. Neurol. 2009, 219:126-135.
116. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. USA 1982, 79:5485-5489.
117. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
118. Tatemoto K., Rökaeus A., Jörnvall H., McDonald T.J., Mutt V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett. 1983, 164:124-128.
119. Tortella F.C., Holaday J.W. Dynorphin A (1-13): in vivo opioid antagonist actions and non-opioid anticonvulsant effects in the rat flurothyl test. NIDA Res. Monogr. 1986, 75:539-542.
120. Tortella F.C., Long J.B. Characterization of opioid peptide-like anticonvulsant activity in rat cerebrospinal fluid. Brain Res. 1988, 456:139-146.
121. Van der Lely A.J., Tschöp M., Heiman M.L., Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 2004, 25:426-457.
122. Van Raay L., Jovanovska V., Morris M.J., O'Brien T.J. Focal administration of neuropeptide Y into the S2 somatosensory cortex maximally suppresses absence seizures in a genetic rat model. Epilepsia 2012, 53:477-484.
123. Vaught J.L. Substance P antagonists and analgesia: a review of the hypothesis. Life Sci. 1988, 43:1419-1431.
124. Vezzani A., Serafini R., Stasi M.A., Viganò G., Rizzi M., Samanin R. A peptidase-resistant cyclic octapeptide analogue of somatostatin (SMS 201-995) modulates seizures induced by quinolinic and kainic acids differently in the rat hippocampus. Neuropharmacology 1991, 30:345-352.
125. Vezzani A., Sperk G., Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999, 22:25-30.
126. Viollet C., Lepousez G., Loudes C., Videau C., Simon A., Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol. Cell. Endocrinol. 2008, 286:75-87.
127. VonVoigtlander P.F., Hall E.D., Ochoa M.C., Lewis R.A., Triezenberg H.J. U-54494A: a unique anticonvulsant related to kappa opioid agonists. J. Pharmacol. Exp. Ther. 1987, 243:542-547.
128. Walker M.C. Basic physiology of limbic status epilepticus. Epilepsia 2009, 50(Suppl. 12):5-6.
129. Weinberg M.S., Samulski R.J., McCown T.J. Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 2013, 69:82-88.
130. Woldbye D.P. Antiepileptic effects of NPY on pentylenetetrazole seizures. Regul. Pept. 1998, 75-76:279-282.
131. Woldbye D.P., Madsen T.M., Larsen P.J., Mikkelsen J.D., Bolwig T.G. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res. 1996, 737:162-168.
132. Woldbye D.P., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat. Med. 1997, 3:761-764.
133. Woldbye D.P.D., Nanobashvili A., Husum H., Bolwig T.G., Kokaia M. Neuropeptide Y inhibits in vitro epileptiform activity in the entorhinal cortex of mice. Neurosci. Lett. 2002, 333:127-130.
134. Wykes R.C., Heeroma J.H., Mantoan L., Zheng K., Macdonald D.C., Deisseroth K., Hashemi K.S., Walker M.C., Schorge S., Kullmann D.M. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med 2012, 4:161ra152.
135. Xu Z.Q., Shi T.J., Hökfelt T. Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J. Comp. Neurol. 1998, 392:227-251.
136. Xu J., Wang S., Lin Y., Cao L., Wang R., Chi Z. Ghrelin protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats. Neurosci. Lett. 2009, 453:58-61.
137. Zafar R., King M.A., Carney P.R. Adeno associated viral vector-mediated expression of somatostatin in rat hippocampus suppresses seizure development. Neurosci. Lett. 2012, 509:87-91.
138. Zini S., Roisin M.P., Langel U., Bartfai T., Ben-Ari Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 1993, 245:1-7.